[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 143.00 151.00 170.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 457

Amryt Pharma Share Discussion Threads

Showing 5201 to 5224 of 7125 messages
Chat Pages: Latest  213  212  211  210  209  208  207  206  205  204  203  202  Older
DateSubjectAuthorDiscuss
30/10/2019
12:04
Yes, interesting when Bronxville posts positive things about Amryt! You know for sure that he now holds some stock. You only have to wait around the corner for when he has sold his stake in Amryt - before he starts spouting out negativity again :) Anyway, I agree that Amryt is undervalued at the moment. I wonder where the figure of 8.8 times revenue came from? I suspect US-based biotech companies - hence a more realistic figure of 5-6 times revenue is likely more achievable with our AIM listing. We'll need to wait for the NASDAQ listing for the £5.34 target to be a reality. I appreciate how Amryt have structured the CVRs. If Episalvan (AP101) fails in Ph3, I do not expect Amryt share price to take a significant hit now, because valuation is underpinned by Lojuxta and Myaleptin revenues. The CVRs, in my opinion, have been funded mainly by the FDA Priority Voucher. If AP101 gets FDA approval, then they are due the windfall of the Priority Voucher, worth circa $100 million. The money from the voucher, I believe, will be channelled towards the CVRs, which milestones are largely based on FDA approval (though smaller proportion based on EMA approval and hitting revenue targets for AP101).
diamondstar1
30/10/2019
11:24
Good post by Bronxville on the lse bb Bronxville Posts: 1,277 Price: 116.60 No Opinion Stifel's price target 29 Oct 2019 22:10 Another Shire Pharma? Its story is similar to that of Shire, founded by the company's chairman Harry Stratford, which grew to be one of the nation’s top 50 largest businesses, developing a portfolio of niche medications. “We wanted to create a new investment thesis,” said CEO Wiley. “We wanted to say you can invest in a solid business that will generate cash flow; that is sustainable into the future and will grow with the upside of potential new drugs and the other development pipeline opportunities we have.” What the broker says Stifel’s Herrmann reckons Amryt and Aegerion are stronger together. He reckons sales from sales from Lojuxta and Myalept will be US$309.5m by 2022. He pointed out that revenue-generative orphan drug companies trade at 8.8-times historic earnings. On that basis, Amryt would be worth US$1.2bn, or 89p a share >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Stifel's price target was obviously written before the 1 for 6 consolidation. Hence their price target needs to be adjusted to take that share consolidation into a/c. Their price target for 2022 then becomes 6 x 89p = 534p (£5.34). That price target doesn't include any success achieved with AP101 and AP103. Will the AMYT share price be £5.34 sometime in 2022 even without success from AP101 & AP103? I don't know, but it would be nice if it was! Hopefully it will be higher. Fingers crossed as always! I live in hope!
papillon
29/10/2019
12:53
Bermudashorts, regarding your list of recent Nasdaq biotech IPO's that have recently downsized, or cancelled, because of market sentiment (your post 5077)? I presume all those companies you listed were raising money when listing? AMYT, however, will NOT be raising money when it lists on Nasdaq (it has already raised US$60m) so current market sentiment for new issues will not be so relevant. By the way I wasn't complaining about the delay in AMYT listing on Nasdaq, just commenting on Cathal Friel's over optimistic prediction of October.
papillon
28/10/2019
19:23
Exactly my point - it's early days and too early to be fretting about any expectations set by Cathal Friel. Amryt's advisors will be sounding out the market and most certainly will be able to predict the appetite from investors for AMYT stock.
bermudashorts
28/10/2019
18:44
For all we know they probably are pushing on with the listing, Bermudashorts. After all the Aegerion deal was only finalised 31 days ago. It's still early days. I don't believe anyone can successfully predict the future NBI, Bermudashorts, in the short term. Not even AMYT's advisors! I don't believe that AMYT are delaying listing on Nasdaq until conditions improve, but if they were that's a very risky stance to take because conditions might NOT get any better (and could get a lot worse!!) before the AP101 results are due. Both diamondstar & waterloo make good points in their posts.
papillon
28/10/2019
18:20
Ditto SLN in the 60's (even though I'm not a fan of the company). Catching up with US peers. Been in and out for years.
waterloo01
28/10/2019
18:19
Papillon, Yes you're right, they may push on because they may believe conditions will worsen on the other hand they may believe they'll improve in which case, I'm sure you'll agree that the push on regardless strategy would not be the right one. Either way, I'm sure they'll be rewarding their advisors handsomely for their advice and will no doubt be following their guidance.
bermudashorts
28/10/2019
18:17
Was lucky enough to be buying SLN in the 40s not long ago. Hopefully something similar here?
volsung
28/10/2019
18:16
I agree with Paps - list ASAP. Amryt is not a small virtual biotech company anymore. It has 2 Marketed Products with good revenue. Biotechs and pharmas are also generally more resistant to downturns. Look what is happening Silence Therapeutics share price at the moment - multi-bagger for those who are brave to buy a few months ago!
diamondstar1
28/10/2019
17:54
The Nasdaq Biotech Index (NBI) has been going sideways between 3000 and 3600 during 2019. Currently it's around midway, circa 3350, between those 2 extremes, Bermudashorts. So though you have quoted those recent biotech IPO's being downsized, or cancelled, the NBI has performed well this month (up by almost 10% since the start of October) so sentiment doesn't seem that bad at the moment. hTTps://indexes.nasdaqomx.com/Index/History/NBI PS Wiley said that the Nasdaq listing would happen within 90 days of the Aegerion deal being finalised. We are only 31 days into that 90. You state "Surely rather that push ahead regardless, the correct strategy is to bide their time and proceed when market conditions are right?" However the market conditions might NOT improve over the next 60 days, Bermudashorts. In fact they could get worse!! Far better to list ASAP.
papillon
28/10/2019
16:44
Bermuda, I don't know much about the above mentioned companies but I would have thought that as AMYT have a combined very decent revenue stream, it puts them somewhat in a different boat to biotechs who are reliant purely on ongoing trial results. AMYT will also need to get this done before Ap101 read out, in case it's negative. If they do it after the price would be very different with the risk side of the company removed (one way or the other). IMO
waterloo01
28/10/2019
16:28
No, I'm not referring to WeWork, I'm talking only about NASDAQ biotech IPOs which is, of course, what is relevant here. Some examples over recent weeks. Rapt Therapeutics - IPO initially cancelled and then downsized ADC Therapeutics - IPO cancelled due to adverse market conditions BioNTech - downsized with lower valuation Vir Biotechnology - downsized and raised at lowest end of price range Frequency Therapeutics - downsized and raised at lowest end of price range Monopar Therapeutics - IPO cancelled due to adverse market conditions Inate Pharma - downsized I'm sure there are others. Of course sentiment and investor appetite can turn on a shoestring but the point still stands - market conditions have not been great for biotech IPOs onto NASDAQ and Amryt will just have to follow the advice of their advisors and go ahead at the optimum time.
bermudashorts
28/10/2019
15:33
The Dow Jones & S&P 500 are in bullish territory at the moment, Bermudashorts, according to the Ichimoku charts. I'll check on the Nasdaq later. Regarding IPO's being pulled in recent weeks I presume you are alluding to WeWork, a business that was acknowledged as being vastly over valued months ago. In fact there were newspaper reports to that effect early this year, so the fact that the WeWork float was pulled and that Softbank have now valued it at a fraction of what the "disgraced" founder thought it was worth should have come as no surprise. As to why Friel's prediction hasn't come to pass (though there are 3 trading days left in October!) it's all guesswork I'm afraid. I think it was just Friel being over optimistic; after all it's only 31 days since the Aegerion deal was finalised and Wiley did state the Nasdaq listing would happen within 90 days of that deal being finalised. We are only a third of the way through that 90 days.
papillon
28/10/2019
12:37
They will be at the mercy of market conditions and they're not good at the moment!! Recent weeks have seen IPOs being pulled or downsized and disappointing valuations. Surely rather that push ahead regardless, the correct strategy is to bide their time and proceed when market conditions are right?
bermudashorts
28/10/2019
12:05
Still "All Quiet on the (Nasdaq) Front"! It's beginning to look like Cathal Friel's AMYT Nasdaq listing in October prediction was rather over optimistic.
papillon
25/10/2019
14:45
Signs of life in the sp! Some very big trades going through all of a sudden. Nasdaq listing date imminent?
papillon
24/10/2019
11:24
radar Posts: 2,993 Price: 115.50 No Opinion Now Today 08:35 This could tank in the absence of news. Those investors who paid £1.41, well .................... >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> The above is the latest post from old misery guts, radar, on the lse bb. I'll finish off his last sentence for him .. .. "Those investors who paid £1.41, well THEY GOT THEIR CVR's!! To get those CVR's they had to pay over the odds for their AMYT shares. Will that prove to be wise, or not? Only time will tell. By leaving their purchase of AMYT shares to the last minute, rather than buying sooner (just after it relisted) they paid more for their shares (I topped up twice at £1.05 and £1.07). That wasn't wise!
papillon
22/10/2019
16:20
Cionnathagad Posts: 52 Price: 115.50 Strong Buy Inquiry about AP103 Today 15:20 Called the company this morning re yesterdays news management are at a Board of Directors meeting in NY. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> "management are at a Board of Directors meeting in NY." I like that!! Does a BoD meeting in NY imply that the Nasdaq listing is near? I hope so! PS. 25k buy today, but 50k sell reported just before close. Hopefully the seller will live to regret selling and soon.
papillon
22/10/2019
11:03
Timbo, Thanks for that. Haven't seen the Rhys video before, his suffering is utterly heartbreaking. "Everywhere sore, painful every day, 24/7 just pain" Re. the CVR's, not sure who your ISA is with but mine are sitting in my HL ISA a/c and apparently will be moved out shortly into my normal trading a/c. Might be worth a call to your broker as I understand there's a 30 day deadline.
bermudashorts
22/10/2019
10:33
Thanks BS I see that Amryt are at both the Shares Mag and Proactive investor meetings this week (tomorrow and Thursday), so I will probably go along to one or both On the subject of CVRs, I hold a few Amryt shares on a certificate and a few in the ISA, I have now received 3 additional certificates for the CVRs, but there is nothing showing in my ISA account or in notifications to tell me that the CVRs have been allocated and need to be transferred out. Lastly, I found this short video on Rhys, a 14 year old boy with very severe EB on BBC iplayer. It was first shown on Sept 23rd, but I am not sure whether it has been posted here before: https://www.bbc.co.uk/iplayer/episode/p07p2wbk/your-world-the-boy-whose-skin-is-peeling
timbo003
21/10/2019
18:33
Link below to latest presentation from Kieran Rooney Https://www.sharesmagazine.co.uk/video/amryt-pharma-kieran-rooney-vice-president-ie
bermudashorts
21/10/2019
10:43
From the lse bb: Bronxville Posts: 1,265 Price: 116.50 No Opinion AMRYT'S baby Today 08:42 Irish scientists announce breakthrough on genetic skin disease 21/10/2019 - 06:36 By Press Association Irish researchers have announced a breakthrough in the search for a cure for a painful skin disease. Epidermolysis bullosa (EB) is a genetic condition in which sufferers lack a vital protein responsible for binding skin. This results in painful blisters – both internal and external – from the slightest knock or bump. The disease affects approximately 300 people in Ireland. Researchers at University College Dublin (UCD) say they have now produced a solution that uses gene therapy to repair bad cells. The best part of this therapy is that it would not involve painful skin grafting procedures or risks associated with viral treatments in delivering functioning genes to the skin The breakthrough has the potential to provide a permanent cure for patients with Recessive Dystrophic EB, one of the most severe sub-types of the disease, for which no treatment currently exists. The concept has been pioneered by Professor Wenxin Wang, who has been carrying out research into EB for the past 10 years, with assistance from the charity Debra Ireland. Dr Jonathan O’Keeffe Ahern, one of the leading gene therapy researchers in Professor Wang’s team, said one of the greatest benefits of the solution is that it removes the need for painful surgery. “The best part of this therapy is that it would not involve painful skin grafting procedures or risks associated with viral treatments in delivering functioning genes to the skin,” he said. Gene therarpy researchers Dr Irene Lara-Saez and Dr Jonathan O’Keeffe Ahern (Shane O’Neill/PA) “We call this the Fed Ex of gene editing – we deliver a biological solution using a simple carrier system. “Rather like using a postcode, we can send in a genetic scissors to cut out the non-functioning part of a gene and then the repaired cells know to fill that space and permanently repair the gene. “We would not need to even take the patient cells for skin grafting. The gel would be applied, absorbed and go to work. “We have seen some promising results in the lab. With further research, we could expand this to other EB types and even other genetic conditions. “We are in the process of forming our own spin-out company to continue to develop this technology and take it to the next step, a clinical trial.” Debra Ireland head of research Dr Sinead Hickey (centre) with Dr Jonathan O’Keeffe Ahern and Dr Irene Lara-Saez, of the University College Dublin gene therapy research team (Shane O’Neill/PA) Debra Ireland provides day-to-day help and support for EB patients and their families and also works to find better treatments and possible cures for EB. This week (October 21-27) is National EB Awareness Week and the charity is asking the public to get involved by wearing a butterfly tattoo to raise awareness for this rare disease and funds for further . Cionnathagad Posts: 51 Price: 116.50 No Opinion RE: AMRYT'S baby Today 09:49 Sounds good. Amryt has licensed this therapy as AP103.I just picked up another 4k to have a nice round figure. Bronxville Posts: 1,265 Price: 116.50 No Opinion RE: AMRYT'S baby Today 10:05 Here's hoping we get fast track approval.. That's my 10k earlier...I've too much tied up in BOI at the moment to buy more...(: Bronxville Posts: 1,265 Price: 116.50 No Opinion RE: AMRYT'S baby Today 10:22 It sounds to me like this therapy could be used for other skin conditions.. I'm wondering about Melanoma? Diamondstar might know..
papillon
21/10/2019
08:38
University College Dublin have found a cure for Recessive Dystrophic EB. Thank God. Heard it on the radio just now. It's EB awareness week .
chica1
20/10/2019
17:52
90 days could take us into December, ab321. Obviously Cathal Friel was being more optimistic. Was his optimistic forecast nothing more than just wishful thinking? 4 share trades Wednesday for 45 shares. 4 trades Thursday for 3862 shares. 2 trades Friday for 1888 shares. So just 4795 shares traded over 3 days at a total cost of £6425 and 20p. This for a company with a Mkt Cap of around £180m. The MM's will soon be passing round the hat and the begging bowl! LOL.
papillon
Chat Pages: Latest  213  212  211  210  209  208  207  206  205  204  203  202  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220122 00:32:59